[HTML][HTML] RanBPM (RanBP9) regulates mouse c-Kit receptor level and is essential for normal development of bone marrow progenitor cells

S Puverel, E Kiris, S Singh, KD Klarmann, V Coppola… - Oncotarget, 2016 - ncbi.nlm.nih.gov
S Puverel, E Kiris, S Singh, KD Klarmann, V Coppola, JR Keller, L Tessarollo
Oncotarget, 2016ncbi.nlm.nih.gov
Abstract c-Kit is a tyrosine kinase receptor important for gametogenesis, hematopoiesis,
melanogenesis and mast cell biology. Dysregulation of c-Kit function is oncogenic and its
expression in the stem cell niche of a number of tissues has underlined its relevance for
regenerative medicine and hematopoietic stem cell biology. Yet, very little is known about
the mechanisms that control c-Kit protein levels. Here we show that the RanBPM/RanBP9
scaffold protein binds to c-Kit and is necessary for normal c-Kit protein expression in the …
Abstract
c-Kit is a tyrosine kinase receptor important for gametogenesis, hematopoiesis, melanogenesis and mast cell biology. Dysregulation of c-Kit function is oncogenic and its expression in the stem cell niche of a number of tissues has underlined its relevance for regenerative medicine and hematopoietic stem cell biology. Yet, very little is known about the mechanisms that control c-Kit protein levels. Here we show that the RanBPM/RanBP9 scaffold protein binds to c-Kit and is necessary for normal c-Kit protein expression in the mouse testis and subset lineages of the hematopoietic system. RanBPM deletion causes a reduction in c-Kit protein but not its mRNA suggesting a posttranslational mechanism. This regulation is specific to the c-Kit receptor since RanBPM reduction does not affect other membrane proteins examined. Importantly, in both mouse hematopoietic system and testis, RanBPM deficiency causes defects consistent with c-Kit loss of expression suggesting that RanBPM is an important regulator of c-Kit function. The finding that this regulatory mechanism is also present in human cells expressing endogenous RanBPM and c-Kit suggests a potential new strategy to target oncogenic c-Kit in malignancies.
ncbi.nlm.nih.gov